BMO Capital Maintains Outperform on AstraZeneca, Lowers Price Target to $80
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Etzer Darout has maintained an Outperform rating on AstraZeneca (NASDAQ:AZN) but has lowered the price target from $82 to $80.

February 12, 2024 | 2:59 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
AstraZeneca's Outperform rating is maintained by BMO Capital, though the price target is reduced from $82 to $80.
The adjustment in price target by a reputable analyst could influence investor sentiment, potentially leading to short-term price fluctuations. However, the maintenance of an Outperform rating suggests a continued positive outlook on the company's performance, which might mitigate any negative impact from the lowered price target.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100